|
Video: What is a Stock Split?
|
|
Immunic is a clinical-stage biopharmaceutical company. Co. is pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase; the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. According to our IMUX split history records, Immunic has had 1 split. | |
|
Immunic (IMUX) has 1 split in our IMUX split history database. The split for IMUX took place on April 15, 2019. This was a 1 for 40 reverse split, meaning for each 40 shares of IMUX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.
When a company such as Immunic conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the IMUX split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immunic shares, starting with a $10,000 purchase of IMUX, presented on a split-history-adjusted basis factoring in the complete IMUX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$492.80 |
|
End price/share: |
$1.27 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.74% |
|
Average Annual Total Return: |
-44.91% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$25.79 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
04/15/2019 | 1 for 40 |
|
|